NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$24.42
+0.48 (+2.01%)
Close of Nov 06, 2026 · end-of-day data
PRVA 8-K filings in 2025
Every material Form 8-K Privia Health Group filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Privia Health reported third-quarter 2025 revenue of $580.4 million, up 32.5% from a year earlier, and net income attributable to the company of $6.9 million, up from $3.5 million. The company raised its full-year 2025 outlook, including GAAP revenue guidance of $2.05 billion to $2.1 billion and Adjusted EBITDA guidance of $118 million to $121 million, both above prior ranges.
Q3 2025 total revenue was $580.4 million, up 32.5% from $437.9 million in Q3 2024.
Net income attributable to Privia Health Group was $6.9 million, or $0.05 per diluted share, versus $3.5 million, or $0.03, a year earlier.
Updated FY2025 guidance: GAAP revenue $2.05 billion to $2.1 billion (previously $1.8 billion to $1.9 billion); Adjusted EBITDA $118 million to $121 million (previously $105 million to $110 million).
Pending acquisition of Evolent Health's ACO business for $100 million in cash plus up to $13 million more, expected to close in Q4 2025; the company had $441.4 million in cash and no debt at September 30, 2025.
Privia Health reported second-quarter 2025 total revenue of $521.2 million, up 23.4% from a year earlier, and raised its full-year 2025 guidance. GAAP net income attributable to Privia shareholders fell to $2.7 million from $3.5 million, while non-GAAP adjusted net income per diluted share rose to $0.24 from $0.19. The results are preliminary and unaudited until the company's Form 10-Q is filed.
Q2 2025 total revenue was $521.2 million, versus $422.3 million in Q2 2024, up 23.4%.
Q2 net income attributable to Privia shareholders was $2.7 million, or $0.02 per diluted share, versus $3.5 million, or $0.03, a year earlier.
Q2 Adjusted EBITDA was $29.0 million, up 31.6% from $22.0 million.
Updated FY 2025 guidance includes GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million, both above the high end of the prior range.
Privia Health Group expanded its board from nine to ten directors and elected Lance Berberian as a Class III director effective July 15, 2025, with a seat on the Audit Committee. The former Labcorp technology chief brings IT, cybersecurity and digital transformation experience to the board, according to the filing.
Board size increased from nine to ten directors; Berberian elected effective July 15, 2025
Berberian appointed to the Audit Committee effective July 15, 2025
Director pay includes an annual cash retainer and restricted stock units with a grant date fair value of $200,000
Berberian served as EVP and Chief Information and Technology Officer at Labcorp from 2014 to October 2024
Privia Health reported first-quarter 2025 revenue of $480.1 million, up 15.6% from a year earlier, and net income attributable to the company of $4.2 million, up from $3.0 million. The company raised its full-year 2025 outlook to the mid-to-high end of most guidance ranges, with attributed lives unchanged, and said it entered Arizona through a $95 million cash acquisition of Integrated Medical Services.
Q1 2025 total revenue was $480.1 million, up from $415.2 million; operating income was $5.2 million, compared with $0.8 million
Net income per share was $0.03, compared with $0.02 in Q1 2024; non-GAAP adjusted net income per share was $0.22, compared with $0.18
Full-year 2025 GAAP revenue guidance is $1.8 billion to $1.9 billion, with most metrics raised to the mid-to-high end of ranges; attributed lives guidance is unchanged
On April 9, 2025, the company entered Arizona with the $95 million cash acquisition of Integrated Medical Services, which is expected to be profitable starting in Q4 2025
Privia Health amended the employment agreement of Parth Mehrotra on March 3, 2025, through a fifth amendment filed as Exhibit 10.1. The amendment sets a $650,000 annual base salary effective March 24, 2025, an annual bonus of up to 125% of base salary, and a long-term incentive target value of $8 million, all starting with the 2025 performance year.
Base salary set at $650,000 annually, effective March 24, 2025
Annual performance bonus eligibility of up to 125% of base salary, starting with the 2025 performance year
Long-term incentive award target value of $8,000,000, starting with the award to be made in 2025
Amendment dated March 3, 2025, attached as Exhibit 10.1
Privia Health reported fourth-quarter 2024 revenue of $460.9 million, up 4.6%, and full-year revenue of $1.74 billion, up 4.7%. Full-year net income attributable to the company fell 37.7% to $14.4 million, while non-GAAP adjusted net income rose 19.8%, and the company gave 2025 guidance for GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million.
Q4 2024 net income attributable to Privia was $4.4 million, up from $2.8 million; diluted EPS was $0.03 versus $0.02
Full-year 2024 diluted EPS was $0.11 versus $0.19 in 2023, a 42.1% decline; non-GAAP adjusted diluted EPS rose 21.9% to $0.78
Full-year 2024 Adjusted EBITDA was $90.5 million, up 25.2%; year-end cash was $491.1 million with no debt
2025 guidance: GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million; guidance assumes no new business development activity
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Privia Health Group filing is on SEC EDGAR ↗. 8-K briefs of other companies →